SINGH & SINGH®

singhandsingh.com

LEGALLY ROOTED® NEWSLETTER

OCT 2026 | ISSUE 14



Dear Readers,

Welcome to the 14th Issue of Singh & Singh Law Firm LLP's Newsletter. We're excited to bring you the latest developments in the ever-evolving world of Intellectual Property (IP) litigation.

In this edition, we highlight the recent landmark decisions in patent and competition law, including the pivotal victories we secured for our clients.

Copyright © Singh & Singh Law Firm LLP

In This Issue

Featured Case

The Hon'ble Delhi High Court grants an ad-interim injunction protecting Zydus Lifescience's trademarks. 03

Supreme Court directs its e-Committee to consider and make corrections to the VCourts website (including compounding of traffic offences) 05

Key Case Updates at the Firm

1. Delhi High Court Restrains Lava from Transferring or Alienating Equity Shares 07
2. Hotel Cancels Ahmedabad Booking for Coldplay Concert Last Minute; Court Orders Refund + Compensation + Litigation Costs 09
3. Supreme Court upholds the Division Bench's Judgement in favour of Intas Pharmaceuticals 10
4. Delhi High Court Restrains Havai from Using Trademark Similar to Havells 12

Featured Publications 13

Recognition & Awards 16





The Hon'ble Delhi High Court grants an ad-interim injunction protecting Zydus Lifescience's trademarks.

Case Reference: Zydus v IndiaMart - CS(COMM) 762/2026

Overview of the Case

The dispute arose from a trademark infringement and passing off suit instituted by Zydus Lifesciences against 'IndiaMart InterMesh Limited' and another Defendant 'Medicine Planet' before the Hon'ble Delhi High Court. The Plaintiff obtained information that its cancer medication under the brand 'IKRA' and house mark 'ZYDUS', was being sold under an identical medicine without Plaintiff's permission. All features of the impugned product were identical to the Plaintiff's product, except that the brochure available for the said listing belonged to a third-party medicine 'VENCLEXTA', thereby resulting in misbranding of a cancer drug. The Plaintiff thus sought an ad-interim injunction to prevent the manufacture and sale of the infringing products as well as a takedown order against Defendant No.1.



Zydus' product IKRA shown above, copied completely by the Defendant

The Defendant No.1 'IndiaMart' gave an undertaking on the first listing of the matter itself that infringing listings would be taken down. The Hon'ble Court noted the undertaking from Defendant No.1 and directed the platform to remove the said listings within 3 days and subsequently to provide an affidavit of compliance. Against Defendant No.2, the Hon'ble Court found a prima facie case of trademark infringement and granted an ad-interim injunction in favour of Zydus, restraining the Defendant No.2 from manufacturing, marketing, or selling the impugned medicinal products.

Significance of the Order

The order highlights the strict stance of the judiciary to protect life-saving pharmaceutical products, ensuring patient safety and health. The Hon'ble Court promptly injuncted the infringing products which were misbranded. It also reaffirms the role of e-commerce platforms and intermediaries in promptly acting to take down infringing listings upon notice, thereby curbing the circulation of deceptive medical products.

Additionally, the Hon'ble Court was pleased to appoint a Local Commissioner to visit the Defendant No.2's premises to search and seize all infringing products, packaging materials, and incriminating records.

Members involved in the case



Bitika Sharma
Senior Partner



Vrinda Pathak
Partner



Rinkoo Kakkar
Senior Associate



Rajnish Kumar
Associate)



Sandhya Kukreti
Associate)



Supreme Court directs its e-Committee to consider and make corrections to the VCourts website (including compounding of traffic offences)

Overview of the Case

Singh & Singh represented the Petitioner in the PIL Prabhjot Singh Dhillon vs. e-Committee, Supreme Court of India & Anr. before the Hon'ble Supreme Court of India.

The PIL stemmed from the VCourts portal managed by the e-Committee of the Supreme Court, where citizens are unknowingly pleading guilty when they pay a fine, instead of compounding (not guilty and pay a fine) - as prescribed in the Motor Vehicles Act.

Another issue of notifications not being received was also raised, recommending the adoption of SMS and email notifications.

The Hon'ble Delhi High Court had made recommendations to the Hon'ble Supreme Court's e-Committee to fix these issues in the matter Benetton India Private Limited vs. State NCT of Delhi.

Describing these issues as "of paramount importance", the 3 judge bench of the Hon'ble Supreme Court, comprising of Chief Justice of India Surya Kant and Justices Joymalya Bagchi and V Mohana, has now directed the e-Committee of the Supreme Court to take these suggestions into consideration and endeavour to make the necessary corrections, including:

- allowing compounding of offences on the VCourts website as well as timely; and
- effective notifications through SMS and email.

The Petitioner, Prabhjot Singh Dhillon, was represented by Senior Advocate Maninder Singh along with...

Members involved in the case



Karmanya Singh Sareen
Managing Partner



Krishnagopal Abhay
Partner



Pari Bhardwaj
Senior Associate

Also covered by:
Bar and Bench: https://www.barandbench.com/news/supreme-court-asks-e-committee-to-provide-for-compounding-of-offences-on-e-courts-portal
ETV Bharat:
https://www.etvbharat.com/en/bharat/supreme-court-asks-e-committee-for-changes-to-e-courts-portal-enn26083106434



Delhi High Court Restrains Lava from Transferring or Alienating Equity Shares

Case Reference: TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) vs LAVA INTERNATIONAL LIMITED: EX(P) 58/2026

Overview of the Case

In an execution petition filed by Ericsson seeking realisation of decretal amount of INR 244 crores, along with interest and cost, the High Court of Delhi has ordered that Lava cannot sell/transfer/alienate its equity shares till the next date of hearing.

These Equity shares of Lava were attached in OMP(EFA)(COMM) 4/2024. Now, the Court has ordered that Lava cannot sell/transfer/alienate these equity shares till the next date of hearing, even if the order dated 11.11.2024 in OMP(EFA)(COMM) 4/2024 is vacated or modified or varied.

ERICSSON, was represented by: Mr. Sandeep Sethi, Senior Advocate with...

Members involved in the case



Saya Choudhary
Senior Partner



Ashutosh Kumar
Senior Partner



Kunal Vats
Partner



Vinod Chauhan
Associate Partner




Radhika Pareva
Senior Associate



Maitreyi Joshi
Associate



Vishwambher Bareja
Associate



Hotel Cancels Ahmedabad Booking for Coldplay Concert Last Minute; Court Orders Refund + Compensation + Litigation Costs

Case Reference: Anirudh Soman vs. Fab Hotels - DC/78/CC/21/2025

Overview of the Case

In a recent case handled by our firm, our Client (a consumer) booked a hotel room well in advance for the Coldplay concert in Ahmedabad. A month later, the hotel unilaterally cancelled the confirmed booking, only to list the same room at a heavily inflated price due to the high demand. This forced our Client to book for an alternative accommodation at a much higher price, making him lose out on the early bird advantage.

The District Consumer Commission held the hotel accountable, ruling this as an unfair trade practice and directing them to pay interest, compensation, and legal costs.

For our Client, Mr. Anirudh Soman, it was never about the final amount. It was about calling out illegal practices that ruin customer experiences and bring disrepute to the country's hospitality industry.

The Petitioner, Anirudh Soman, was represented by:

Also covered by https://lnkd.in/dFKP76S4 **IndianExpress**


Members involved in the case



Krishnagopal Abhay
Partner



Pari Bhardwaj
Senior Associate



Bhavya Sharma
Senior Associate



Supreme Court upholds the Division Bench's Judgement in favour of Intas Pharmaceuticals

Case Reference: Sun Pharma Laboratories Limited vs Intas Pharmaceutical Limited | SLP (C) No. 23851 of 2026

Overview of the Case

Hon'ble Supreme Court puts to rest pharmaceutical trademark dispute between Sun Pharma and Intas Pharmaceuticals for cancer drugs - BEVETEX vs BEVATAS

The Hon'ble Supreme Court of India has rendered its decision on the BEVATAS vs BEVETEX trademark dispute for rival cancer drugs after Sun Pharma filed a Special Leave Petition under Article 136 of the Constitution of India challenging the Delhi High Court Division Bench's Judgement dated 29.05.2026 in Intas Pharmaceuticals Limited v. Sun Pharma Laboratories Limited [RFA (OS) (COMM) 10 of 2026]. The Hon'ble Division Bench had found the rival marks to be dissimilar and set aside the Ld. Singe Judge's finding of infringement and deceptive similarity.

Prior to the Division Bench's judgement, which was
rendered in a record time of 2 months, the Ld. Single Judge had ruled that BEVATAS infringed BEVETEX, injuncted Intas Pharmaceuticals from using the mark BEVATAS and has decreed the suit in Sun Pharma's favour.

After hearing the parties and on careful consideration of the matter, the Hon'ble Supreme Court orally opined that the Division Bench has been too harsh on the Plaintiff and proceeded to set aside paragraphs 155(a) [plaint being vexatious] and 158 & 159 [costs imposed on Plaintiff]. The Hon'ble Supreme Court held that there was no ground to interfere with the remaining part of the Division Bench's Judgment, which has been consequently upheld.

In light of the Hon'ble Supreme Court's confirmation of the Division Bench's Judgement dated 29.05.2026, the following principles of law are settled:

1. Even though Cadila Health Care Ltd. vs Cadila Pharmaceuticals Ltd. [(2001) 5 SCC 73] calls for a stricter test for pharmaceutical trademarks, the mere similarity of rival trademarks does not automatically warrant the grant of an injunction. When the rival trademarks are not identical the factors laid down in paragraphs 35 and 36 of Cadila ought to be applied to the facts of each case to assess the likelihood of confusion.
2. When the rival marks are not identical, evidence from the relevant class of the public is necessary to establish likelihood of confusion. At the final stage of the proceedings, a prima facie view formed from the Judge's own comparison of the rival trademarks, without such evidence, would not suffice.
3. The person of average intelligence with imperfect recollection with respect to whom deceptive similarity is assessed is not a layman, but has to be chosen considering a reasonably prudent person of the relevant class of public who are exposed to and would purchase and use the goods bearing the rival marks in the course of trade.
4. The mere fact that the rival trademarks relate to pharmaceutical products or products falling under Class 5 does not, by itself, mean that the goods are identical. Where the goods are not therapeutic substitutes for each other, they cannot be regarded as identical goods under Section 29 of the Trade Marks Act.
5. A Plaintiff must disclose clear facts constituting the cause action and plead the relevant sub-section under Section 29 of the Trade Marks Act, failure whereof may render the plaint liable to be rejected at the threshold.

The Respondent Intas Pharmaceuticals Limited was represented by Senior Advocates Dr. Abhishek Manu Singhvi and Mr. Amit Sibal, along with...

Members involved in the case



Bitika Sharma
Senior Partner



George Vithayathil
Associate Partner



Ahaana Singh Rana
Associate



Delhi High Court Restrains Havai from Using Trademark Similar to Havells

Case Reference: Havells India Limited & Anr. v. Havai Home Products Pvt. Ltd. & Ors. CS(COMM) 778/2024

Summary

The Delhi High Court has restrained Havai Home Products and Advance Coolers from selling or advertising electrical goods under the 'HAVAI' mark, finding it deceptively similar to Havells' registered trademark. The Court observed that altering the stylisation of the letter 'I' to resemble an 'L' could mislead consumers into associating the products with Havells. It held that Havells had established a prima facie case of passing off and granted an interim injunction pending the final decision in the suit.

Featured Publication



Viewpoint

The Indian Trade Marks Registry is moving towards greater digitisation, transparency, and efficiency. While technology-driven reforms are streamlining trademark processes, infrastructure issues and procedural delays remain key challenges.

Authors

Mohit Wadhwa (Partner), Shumi Wasandi (Principal Associate), Rinkoo Kakkar & Tiyasa Banerjee (Senior Associates), Singh & Singh Law Firm LLP

https://www.barandbench.com/law-firms/view-point/recent-developments-at-the-indian-trade-marks-registry-digitisation-transparency-and-efficiency



Viewpoint

The Delhi High Court demonstrated that commercial disputes can be resolved faster through strict case management, streamlined evidence procedures, and technology-assisted hearings. The case highlights how effective implementation of existing rules can reduce delays and improve access to justice.

Author

Sarath Prakash (Senior Associate), Singh & Singh Law Firm LLP

https://www.barandbench.com/law-firms/view-point/this-patent-trial-in-india-took-just-3-months-a-model-for-all-commercial-cases



Viewpoint

AI-assisted inventions are challenging traditional patent laws across India, the US, and Europe. While AI cannot legally be recognised as an inventor, humans who make meaningful contributions using AI may secure patent protection, highlighting the need for evolving IP frameworks.

Author

Archana Singh (Partner), Karmanya Singh Sareen (Managing Partner), Maitreyi Joshi (Associate), Singh & Singh Law Firm LLP

https://www.barandbench.com/law-firms/view-point/mapping-the-global-borderlines-of-ai-assisted-inventions

Firm Recognitions & Awards









© Singh & Singh Law Firm LLP

SINGH & SINGH®

Address

New Delhi
C-139, Defence
Colony New Delhi -
110024 India

Contact

singhandsingh.com
contact@singhandsingh.com
T 011-49876099
T 011-49826000